SUMMARY Fifty-one patients with raised intraocular pressure (IOP) were treated for up to four years with one of three ophthalmic solutions: 0 5% levobunolol, 1% levobunolol, or 0-5% timolol. The study was conducted as a double-masked, randomised trial in which medications were administered twice daily to both eyes. Levobunolol and timolol were equally effective in reducing overall mean IOP; reductions were greater than 8 8 mmHg in all three treatment groups. The study showed levobunolol to be as safe and effective as timolol in the long-term control of raised TOP. 
Glaucoma is a chronic disease, generally requiring a lifetime of treatment. Most evaluations of new agents, however, are of relatively limited durations. In the present report we describe our findings in a four-year, double-masked comparison of levobunolol, a new 131432-adrenoceptor antagonist, and timolol. This is a follow-up to our previous one-year report of this comparison.'
Subjects and methods
As detailed previously,' this was a randomised, double-masked comparison of three treatments: 0.5% levobunolol, 1% levobunolol, or 0-5% timolol. All were administered twice daily into both eyes.
Patients with chronic open-angle glaucoma or ocular hypertension characterised by untreated IOP values of 23 mmHg or higher in both eyes were considered for the study. Excluded from participation were patients with contraindications to the topical or systemic use of beta blockers, those with secondary or narrow-angle glaucoma or aphakia, and those who had used systemic beta blockers within the three months immediately preceding the study.
The study consisted of 35 visits including a baseline examination. After the baseline examination and as close as possible to Week groups. Most of the efficacy failures occurred within the first two years of the study. The status of all the patients at the end of the study is shown in Table 2 . In addition to the patients whose treatment was terminated owing to inadequate control of IOP, approximately 8% had their treatment terminated for drug-related adverse effects. These were in the two levobunolol groups and included three reports of topical allergies to levobunolol and one report of dyspnoea. All adverse effects occurred after approximately one year of treatment.
As shown in Fig. 2 , there was a significant decrease of mean IOP from baseline in all three treatment groups throughout the four years of the study. Overall, the mean decrease in IOP was 9-5 mmHg, 9*6 mmHg, and 8-8 mmHg in the 0*5% levobunolol, 1% levobunolol and 0-5% timolol groups, respectively. There were no significant differences among the groups. As shown in Table 3 , there were reports of clinically significant increases in cup/disc ratio (¢0-2) and in progressive visual field loss in approximately one-half of the patients. The treatment groups were similar in this respect.
Overall, the mean changes in pupil size were less than +0-25 mm. Mean decreases in Schirmer tests were less than 2-5 mm. No changes were seen in the blink test. None of these changes was of clinical or statistical significance. While decreases in mean heart rate of 5-10 bpm were observed with the first week of therapy (Fig. 3) , these decreases did not change significantly over time. There were decreases in mean systolic and diastolic blood pressure in all treatment groups (Fig.  4 ). There were no significant differences among groups in overall mean changes in heart rate or blood pressure (Table 4 ). In general, the incidence of clinically significant biomicroscopic and ophthalmoscopic findings were similar among the groups.
Patients' complaints were few, numbering only three. One patient using 0.5% timolol had epiphora at one visit. Another using 0-5% levobunolol reported unilateral trigeminal irritation, which Table 4 Overall mean changes in cardiovascular variables 50o% 10% 0.5% Levobunolol Levobunolol Timolol
Heart rate (bpm)
Systolic blood pressure 1.0
Diastolic blood -0-4 -3-9 -6-7 pressure (mmHg)
There were no significant differences among groups.
resolved within one month. The third, who used 1% levobunolol, reported dizziness at three visits.
Discussion
In this study levobunolol was as safe and effective as timolol for the long-term treatment of raised IOP. However, as is well known, medical or surgical ocular hypotensive therapy may not necessarily halt the glaucomatous process. Some studies suggest that treatment retards the progression rate of glaucoma,'01' others do not.'213 Testing these hypotheses requires evaluation of a group of patients who receive no treatment and long-term follow-up with automated perimetry, as is being undertaken by Alexander and associates.'4 The present study was conducted not to answer the larger question of the efficacy of treatment on. the disease itself but to compare a new ocular hypotensive agent, levobunolol, with a currently accepted one, timolol. In that regard we found both treatments equivalent.
As in other controlled studies, with neither levobunolol nor timolol did we see evidence of punctate keratitis, dry eye, corneal anaesthesia, or other ocular findings previously reported for timolol.67 This suggests that such clinical reports may be relatively rare. Indeed, the frequency of ophthalmic examination in our study, 35 visits over four years, might tend to exaggerate the 'real' incidence.
Our four-year results support the trends we observed in the first year' as well as observations from other studies.6 Levobunolol is as safe and effective as timolol for the long-term control of IOP in patients with glaucoma.
